J&J Medical Connect
SPRAVATO®

(esketamine)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Concomitant Use with Monoamine Oxidase Inhibitors

Last Updated: 10/19/2026

SUMMARY

  • There are no prospective controlled studies evaluating the efficacy or safety of concurrent treatment with monoamine oxidase inhibitors (MAOIs) and SPRAVATO nasal spray.
  • Concomitant use with MAOIs may increase blood pressure. Closely monitor blood pressure with concomitant use of SPRAVATO with MAOIs.1
    • A quasi-experimental study evaluated cardiovascular outcomes from 193 SPRAVATO treatment sessions conducted in 13 patients with treatment-resistant depression (TRD), including 116 sessions involving concomitant non-selective MAOIs
      (NS-MAOIs). No significant differences in systolic blood pressure, diastolic blood pressure, or heart rate elevation were observed between the SPRAVATO-alone and SPRAVATO+NS-MAOI treatment groups. No cases of serotonin syndrome were reported; a case of hypertensive crisis occurred in the SPRAVATO-alone group.2
    • A case series reported the safety results of concomitant use of SPRAVATO and MAOIs in 3 patients with TRD.3
    • A case report described the experience of a 61-year-old female who was taking tranylcypromine and SPRAVATO for TRD.4
  • Please contact the manufacturers of MAOIs for more information regarding their safety and drug-drug interactions.

CLINICAL DATA

Quasi-Experimental Study

Dormegny-Jeanjean et al (2025)2reported cardiovascular outcomes associated with concomitant use of intranasal SPRAVATO and NS-MAOIs in patients with TRD. A total of 193 SPRAVATO treatment sessions conducted in 13 patients were evaluated retrospectively, including 116 sessions involving concomitant NS-MAOI use. Five patients received an
NS-MAOI (4 received tranylcypromine and 1 received phenelzine). Cardiovascular parameters, including systolic blood pressure, diastolic blood pressure, and heart rate, were assessed at baseline and every 30 minutes for 2 hours following SPRAVATO administration.

A Bayesian random model analysis including 12 patients (2 in the SPRAVATO+NS-MAOI group, 7 in the SPRAVATO-alone group, and 3 who received both) was performed to assess and compare changes in cardiovascular outcomes between SPRAVATO groups. Peak increases in cardiovascular parameters from baseline were observed following SPRAVATO administration; however, these changes were mild and not considered clinically significant. Between the SPRAVATO-alone and SPRAVATO+NS-MAOI groups, no significant differences in cardiovascular parameter changes were observed.

An analysis of factors associated with blood pressure elevation using a Bayesian hierarchical model (183 sessions among all 13 patients) demonstrated that concomitant NS-MAOI treatment was not associated with an increased risk of mild blood pressure elevation (odds ratio [OR], 0.66; 95% plausibility interval, 0.04-12.34) or moderate blood pressure elevation (OR, 0.87; 95% plausibility interval, 0.04-17.51). A hypertensive crisis occurred during 1 treatment session in the SPRAVATO-alone group and no cases suggestive of serotonin syndrome were reported. Limitations include the trial design (the retrospective and non-randomized design restricts extrapolation of the results) and a small sample size.

Case Series

Wallner et al (2023)3 reported 3 cases of concomitant use of SPRAVATO with MAOIs to treat patients with TRD.

  • Case 1: A 74-year-old female patient initially treated with phenelzine was started on concomitant SPRAVATO after failing to achieve remission after 6 months of treatment with phenelzine. During the first treatment with 56 mg SPRAVATO, an increase in the patient’s blood pressure was noted at 40 minutes (137/85 mmHg) and 2 hours (200/99 mmHg) after SPRAVATO administration from baseline (116/79 mmHg). Although the patient remained asymptomatic, she was administered 10 mg amlodipine; blood pressure measurement taken at approximately 3 hours after administration was 110/66 mmHg. At the next SPRAVATO treatment 4 days later, the patient was administered 84 mg SPRAVATO and her afternoon dose of phenelzine (15 mg) was held. In the subsequent blood pressure measurements, an increase was noted at 40 minutes (128/80 mmHg) and 2 hours (142/78 mmHg) after SPRAVATO administration from baseline (101/59 mmHg). Ultimately, the patient was switched from phenelzine to tranylcypromine due to a lack of treatment efficacy with tolerable doses of phenelzine and a decline in cognitive functions. In the remaining 37 SPRAVATO treatments over ~11 months with concomitant phenelzine or tranylcypromine, no significant elevations in blood pressure readings were reported.
  • Case 2: A 32-year-old female patient initially treated with 73 SPRAVATO treatments over 1.5 years was started on concomitant therapy with tranylcypromine due to persistent suicidal ideation. In the subsequent 49 SPRAVATO treatments over ~14 months with concomitant tranylcypromine, no significant elevations in blood pressure readings were reported.
  • Case 3: A 61-year-old female patient initiated on SPRAVATO in the SUSTAIN-3 study was augmented with tranylcypromine after failing to achieve remission after 152 SPRAVATO treatments over 3 years. In the subsequent 9 SPRAVATO treatments over ~2 months with concomitant tranylcypromine, no significant elevations in blood pressure readings were reported.

Case Report

Dunner et al (2020)4 reported on a 61-year-old female patient treated with SPRAVATO concomitantly with tranylcypromine 60 mg. Pertinent medical history included persistent chronic major depressive disorder that was refractory to adequate trials of escitalopram, fluoxetine, bupropion, duloxetine, mirtazapine, augmentation with quetiapine, electroconvulsive therapy, and psychotherapy. The patient experienced a partial response to tranylcypromine therapy initiated at age 57 after a depressive episode.

Treatment was initiated with 28 mg SPRAVATO on the first 2 visits, with blood pressure monitoring every 10 minutes during the first visit. Improvement in anxiety and depression were noted on the first visit. At the third visit, the patient experienced nausea, dizziness, and agitation, with a 56 mg dose resulting in a dose reduction of the final 4 doses of the 4-week treatment. At the end of the acute treatment period, ratings on both patient- and clinician-rated depression and anxiety scales improved and were in the normal range.

Baseline blood pressure ranged from 91-108 mmHg systolic and 56-70 mmHg diastolic. At 40 minutes after dosing, her blood pressure ranged from 99-135 mmHg systolic and       60-82 mmHg diastolic. During treatment, there was no evidence of serotonin syndrome. Mild side effects of dissociation and sedation were observed and dissipated during the 2-hour monitoring period after dosing.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 29 September 2026.

 

References

1 Center for Drug Evaluation and Research. Summary Review. 211243 - SPRAVATO (esketamine) - Reference ID: 4398871. 2019-[cited 2024 June 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000SumR.pdf.  
2 Dormegny-Jeanjean LC, Lenoir S, Humbert I, et al. Cardiovascular effects of non-selective monoamine oxidase inhibitors and intranasal esketamine combination in depression: a quasi-experimental design with Bayesian analyses. Pharmacopsychiatry. 2025;58(06):273-283.  
3 Wallner MA, Eloge JC, Mackey IV, et al. Safety and tolerability of concomitant intranasal esketamine treatment with irreversible, nonselective MAOIs: a case series. J Clin Psychiatry. 2023;84(2):22cr14598.  
4 Dunner DL, Fugate RM, Demopulos CM. Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: a case report. Neurol Psychiatry Brain Res. 2020;36:30-31.  

Would you like to clear and leave your conversation? Message history will be lost.